Heme oxygenase and GCLC can lead to COPD disease aggravation, indicating increasing Nrf2 activity as a treatment strategy in COPD (Digaleh et al., 2013; Niforou et al., 2014; Wu et al., 2015). This evidence concerns the gene NFE2L2 and chronic obstructive pulmonary disease.